



TFW

PATENT  
Customer No. 22,852  
Attorney Docket No. 09095.0009-01000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Wang et al.	)	Group Art Unit: 1614
	)	
Application No.: 10/773,332	)	Examiner: Not Yet Assigned
	)	
Filed: February 9, 2004	)	
	)	
For: ARYL PHENYLHETEROCYCLYL	)	Confirmation No.: 8910
SULFIDE DERIVATIVES AND	)	
THEIR USE AS CELL ADHESION	)	
INHIBITING ANTI-		
INFLAMMATORY AND IMMUNE-		
SUPPRESSIVE AGENTS		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached form PTO/SB/08. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

A copy of the listed document is enclosed.

Applicants respectfully request the Examiner consider the listed document and indicate that it was considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: December 15, 2004

By:   
Maria T. Bautista  
Reg. No. 52,519

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <div style="text-align: center; font-weight: bold; font-size: 1.2em;">           INFORMATION DISCLOSURE STATEMENT BY APPLICANT         </div> <p style="text-align: center; font-size: 0.8em;">(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	10/773,332
				Filing Date	February 9, 2004
				First Named Inventor	Gary Wang
				Art Unit	1614
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	09095.0009-01000

OIPE  
DEC 15 2004  
TRADEMARK DIVISION

Sheet	1	of	1
-------	---	----	---

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**Note:** Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		WANG et al., "Amino-Substituted Heterocycles as Isosteres of Trans-Cinnamides: Design and Synthesis of Heterocyclic Biaryl Sulfides as Potent Antagonists of LFA-1/ICAM-1 Binding", <i>Bioorg. Med. Chem. Lett.</i> , 15:195-201 (2005) (available online as of Nov. 17, 2004 from <a href="http://www.sciencedirect.com">http://www.sciencedirect.com</a> )	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.